Nevertheless, it is noteworthy that patients harboring sensitive EGFR mutations achieved a remarkable RR of 77 % and a median PFS of 9.1 months even in the second- or third-line setting, results that are comparable to the first-line use of gefitinib in EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.